
(A)
Treatment Median (95% CI) HR (95% CI)
TMZ-based chemotherapy 33.9 (13.8-50.9) 0.76 (0.36-1.60)
HDI 22.7 (14.7-40.5) Reference
Logrank P-value: 0.3287
+ Censor
RFS (%)
Months
No. at risk
TMZ-based chemotherapy 25 19 16 13 11 8 6 5 3 3 2 1
HDI 26 23 14 9 7 3 2 1 1 1 1 1
(B)
Treatment Median (95% CI) HR (95% CI)
TMZ-based chemotherapy 114.5 (27.2-NR) 1.23 (0.41-3.67)
HDI 61.4 (42.4-NR) Reference
Logrank P-value: 0.9669
+ Censor
MSS (%)
Months
No. at risk
TMZ-based chemotherapy 25 24 19 16 15 12 7 6 2 2 2 2
HDI 26 26 24 17 13 9 5 3 3 2 1 1
(C)
Treatment Median (95% CI) HR (95% CI)
TMZ-based chemotherapy 18.0 (10.0-22.0) 0.36 (0.24-0.54)
HDI 6.7 (4.6-8.8) Reference
Logrank P-value: <.0001
+ Censor
RFS (%)
Months
No. at risk
TMZ-based chemotherapy 75 45 33 20 15 11 8 8 5 4 1 0
HDI 49 12 6 4 1 1 0 0 0 0 0 0
(D)
Treatment Median (95% CI) HR (95% CI)
TMZ-based chemotherapy 41.4 (34.7-48.5) 0.47 (0.29-0.78)
HDI 25.1 (17.0-34.3) Reference
Logrank P-value: 0.0667
+ Censor
MSS (%)
Months
No. at risk
TMZ-based chemotherapy 75 67 54 44 34 20 17 13 8 6 2 1
HDI 49 43 24 17 8 7 5 2 0 0 0 0